Humankind Investments’s Agilon Health AGL Stock Holding History

Humankind Investments’s Portfolio AGL Stock Details AGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-632	Closed	-$30K	–	150
2024 Q4	$30K	Buy	+632	New	+$38.2K	0.01%	152

Other funds holding AGL

CDR

Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Humankind Investments's AGL Position: Q1 2025 in Review

Humankind Investments sold out of Agilon Health (AGL) in Q1 2025, closing a stake of 632 shares — an estimated $30K sold.

Humankind Investments first reported a position in AGL in Q4 2024 and held it in 1 quarter. The position peaked at $30K in Q4 2024. 197 funds tracked by Wall St. Rank hold AGL as of Q1 2025.

Humankind Investments reported no remaining Agilon Health position as of Q1 2025 after selling out during the quarter.
Humankind Investments sold 632 Agilon Health shares in Q1 2025, an estimated $30K.
Humankind Investments first reported a position in Agilon Health in Q4 2024 and held it in 1 quarter.
Humankind Investments's Agilon Health position peaked at $30K in Q4 2024.
197 funds tracked by Wall St. Rank held Agilon Health as of Q1 2025.

Based on Humankind Investments's 13F filing for Q1 2025, filed 14 May 2025.